Neither compound is FDA-approved for any indication. Both are supplied as research-grade material under the For Research Use Only standard. The published clinical literature on full-length Tβ4 (development codes RGN-259 ophthalmic and RGN-352 injectable) is substantially more developed than the literature on either BPC-157 or the TB-500 heptapeptide fragment specifically — a distinction that matters when reading combination-research claims. There is no peer-reviewed published clinical literature on a fixed-ratio BPC-157 + TB-500 combination product; combination research is limited to anecdotal practitioner reports and a small number of unpublished animal observations.
This guide compares the two compounds across mechanism, evidence base, research applications, and the specific case of the BPC+TB combination. Readers new to the broader field should first review the Beginner’s Guide to Research Peptides for orientation; readers interested in compound-level detail should consult the BPC-157 compound hub and the TB-500 compound hub.
Important Note on the Evidence Base
Important note on the evidence base for both compounds: Peer-reviewed BPC-157 research has been conducted predominantly in rodent injury models (Sprague-Dawley and Wistar rats) and in vitro cell-culture work. Peer-reviewed TB-500-specific research is more limited; most thymosin beta-4 clinical research has been conducted with the full-length 43-amino-acid protein (RGN-259 / RGN-352), not the 17–23 heptapeptide fragment sold as TB-500. Whether the heptapeptide fragment fully recapitulates the parent protein’s tissue-repair effects in vivo is a real, unresolved question in the field. Researchers should interpret both literatures accordingly.
What Each Compound Is
BPC-157 is a synthetic 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV. It was identified as a fragment of a larger protective protein originally isolated from human gastric juice and was advanced into clinical development by the Croatian pharmaceutical company Pliva under the designations PL-10, PLD-116, and PL 14736 for inflammatory bowel disease research. Phase I safety data in healthy volunteers appeared in conference proceedings; a Phase II trial of the PL 14736 formulation in ulcerative colitis was completed but full peer-reviewed efficacy results have not been published. BPC-157 has been described in the literature as stable in human gastric juice without enzymatic degradation, a property that motivated subsequent research designs evaluating oral and topical administration routes.
TB-500 is a synthetic, N-acetylated heptapeptide with the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ). This sequence corresponds to amino acids 17–23 of thymosin beta-4, which is the actin-binding motif of the larger parent protein. The N-terminal acetylation protects the peptide from aminopeptidase degradation, extending its plasma half-life relative to the unmodified fragment. Full-length thymosin beta-4 (43 amino acids) is a ubiquitous actin-sequestering protein found in nearly every mammalian cell type and was advanced into clinical development by RegeneRx Biopharmaceuticals under the codes RGN-259 (ophthalmic) and RGN-352 (injectable). The TB-500 heptapeptide is the form used in equine veterinary medicine and is on the World Anti-Doping Agency prohibited list.
The structural distinction matters for citation interpretation. Most peer-reviewed clinical and mechanistic research published on the thymosin beta-4 family has used the full-length 43-amino-acid protein, not the 17–23 heptapeptide fragment. As of 2026, no published randomized controlled trial in humans has tested the injected TB-500 heptapeptide for any musculoskeletal, cardiac, or systemic indication.
Mechanism: VEGFR2–Akt–eNOS vs G-Actin Sequestration
The two compounds operate through distinct molecular pathways that have minimal overlap at the receptor or signaling-pathway level. The mechanistic descriptions below reflect the predominantly preclinical evidence base for each.
BPC-157: angiogenesis via VEGFR2–Akt–eNOS. The most cited mechanistic finding for BPC-157 comes from Hsieh and colleagues, who used a chick chorioallantoic membrane assay, an endothelial tube-formation assay, and a rat hindlimb ischemia model to investigate the compound’s pro-angiogenic activity [1]. The investigators reported that BPC-157 promoted angiogenesis in the CAM assay and tube-formation assay and accelerated blood-flow recovery in the rat ischemia model, with the effect attributed to upregulation of vascular endothelial growth factor receptor 2 (VEGFR2), with downstream activation of the protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS) pathway. The same broader laboratory program has reported BPC-157 effects on fibroblast migration via the FAK–paxillin pathway, modulation of the nitric oxide system, and upregulation of growth hormone receptor expression in tendon fibroblasts. The convergent mechanistic story is one of vascular and matrix remodeling at the site of injury.
TB-500 / thymosin beta-4: G-actin sequestration and the PINCH–ILK–Akt pathway. Thymosin beta-4 is the major monomeric (G-actin) sequestering peptide in eukaryotic cells; it binds G-actin in a 1:1 ratio and prevents its polymerization into filamentous (F-)actin, thereby regulating the available actin monomer pool for cytoskeletal remodeling. This actin-binding function is the basis for the parent protein’s effects on cell shape, migration, and division. The foundational cardiac-repair mechanism paper from Bock-Marquette and colleagues demonstrated that Tβ4 forms a functional complex with PINCH and integrin-linked kinase (ILK), resulting in activation of the survival kinase Akt; after coronary artery ligation in mice, Tβ4 treatment upregulated cardiac ILK and Akt activity, enhanced early myocyte survival, and improved cardiac function [2]. The Goldstein, Hannappel, and Kleinman review frames Tβ4 as a “moonlighting” actin-sequestering protein with broader pleiotropic activity in dermal wound healing, corneal repair, cardiac repair, and anti-inflammatory contexts [3].
The mechanisms do not converge. BPC-157’s effects in animal models map predominantly to vascular biology (VEGFR2–Akt–eNOS, fibroblast migration via FAK–paxillin, NO-system modulation). Tβ4’s effects map predominantly to cytoskeletal regulation (G-actin sequestration) with a downstream cell-migration and cell-survival profile (PINCH–ILK–Akt). The two compounds are studied in overlapping tissue-repair contexts and both upregulate the Akt survival kinase as a downstream node, but they do so through unrelated upstream mechanisms. Claims that BPC-157 and TB-500 “act synergistically through the same pathway” are not supported by the published mechanistic literature.
Evidence Base Comparison — Both Preclinical-Dominant
Both compounds have evidence bases dominated by preclinical work, but the shape of those evidence bases differs in ways researchers should note.
BPC-157 literature. The BPC-157 corpus consists predominantly of controlled rodent injury studies (Sprague-Dawley and Wistar rats) covering tendon, ligament, gastrointestinal, cardiovascular, and ischemia models, plus in vitro work on fibroblasts, endothelial cells, and tendon explants. The literature has been published in peer-reviewed journals including the Journal of Molecular Medicine, the Journal of Applied Physiology, and the Journal of Orthopaedic Research. A large fraction of the controlled in vivo work originates from the Sikiric laboratory in Croatia. Phase I safety data for the PL 14736 formulation in healthy volunteers appeared in conference proceedings; full Phase II efficacy data for the ulcerative colitis program have not been published in the peer-reviewed literature.
TB-500 / thymosin beta-4 literature. The peer-reviewed corpus for the Tβ4 family is broader at the mechanistic level but more concentrated at the clinical level. The Bock-Marquette 2004 Nature paper is the foundational cardiac-repair mechanism citation [2]; the Goldstein 2005 review remains the most-cited single summary of Tβ4’s pleiotropic biology [3]. Clinically, the strongest published finding for the family comes from a Phase 3 randomized, placebo-controlled, double-masked trial of topical 0.1% RGN-259 (full-length recombinant Tβ4) in patients with neurotrophic keratopathy, in which RGN-259-treated patients showed significantly faster corneal epithelial healing versus placebo with no significant adverse events [4]. The corresponding clinical literature on the injected TB-500 heptapeptide fragment specifically is essentially absent. Researchers reading “TB-500 has Phase 3 trial data” should note that the Phase 3 data refer to full-length Tβ4 in an ophthalmic indication, not to the injected heptapeptide form.
For practical evidence-base purposes:
- BPC-157 evidence base: robust controlled rodent literature; in vitro mechanistic complement; one Phase I safety signal in healthy volunteers; one completed but unpublished Phase II IBD trial.
- TB-500-specific evidence base: animal pharmacology and veterinary literature; no published human RCT of the heptapeptide.
- Full-length Tβ4 evidence base: robust mechanistic literature; published Phase 3 RCT in neurotrophic keratopathy (topical RGN-259); cardiac development program data from preclinical work.
Research Applications
The two compounds are studied in overlapping but distinct research contexts. The summaries below describe the predominant research applications reported in the published literature.
BPC-157 research applications. The published rodent literature has investigated BPC-157 in tendon-to-bone healing (Krivic Achilles detachment model), ligament healing (Cerovecki medial collateral ligament transection model with intraperitoneal, oral, and topical administration), gastrointestinal-injury protection (restraint stress, cysteamine, ethanol, NSAID lesions), and cardiovascular and ischemia models. Common research designs use a microgram-per-kilogram or nanogram-per-kilogram administration range, with administration by intraperitoneal injection, intragastric gavage, oral drinking water, or topical cream. Researchers planning protocols are referred to the primary literature cited on the BPC-157 compound hub for methodological detail.
TB-500 / thymosin beta-4 research applications. The published Tβ4 literature spans dermal wound healing (Treadwell Phase 2 stasis and pressure ulcer trials with full-length Tβ4), corneal epithelial healing (Sosne RGN-259 Phase 3 in neurotrophic keratopathy), cardiac repair post-injury (Bock-Marquette mechanism work; Postrach long-term administration rat MI work), and broader anti-inflammatory and angiogenic applications. Research models using the TB-500 heptapeptide fragment specifically are most commonly seen in equine veterinary contexts and in non-published practitioner literature; published academic research using the heptapeptide is sparse. The structural distinction between the heptapeptide and the full-length protein is not minor: the actin-binding motif is preserved in the heptapeptide, but the broader pleiotropic activity of the parent protein involves additional sequence elements outside residues 17–23.
For research framed around tissue repair more broadly, the Recovery & Healing category also includes GHK-Cu (a copper-binding tripeptide with a substantially longer cosmetic-science literature) and Thymosin Alpha-1 (a structurally unrelated immune-modulation peptide).
Combination Research — The BPC+TB Blend
The two compounds are sometimes combined in research blends and in practitioner contexts. Omnix Peptides supplies a combination preparation under the BPC+TB Blend compound hub. The combination, however, is not supported by peer-reviewed published combination research.
For researchers specifically interested in the combination, the BPC+TB Blend compound hub covers the combination preparation; the individual BPC-157 and TB-500 hubs cover the single-compound literatures.
Available Research Formats
BPC-157 is supplied in three formats: vial (lyophilized powder for reconstitution, available in 5 mg, 10 mg, and 15 mg strengths), capsule (500 mcg per capsule, 60-count bottle), and liquid spray (30 mg per 30 mL bottle). The vial is the canonical research format used in most of the published preclinical literature; the capsule and spray formats extend the research to oral and mucosal-delivery contexts.
TB-500 is supplied in capsule format (500 mcg per capsule, 60-count bottle). Researchers requiring injectable presentation of TB-500 should consult the product page for current format availability. The BPC+TB Blend preparation is supplied in vial, capsule, and spray formats; see the BPC+TB Blend compound hub.
Frequently Asked Questions
Are BPC-157 and TB-500 the same compound?
No. BPC-157 and TB-500 are structurally unrelated, mechanistically distinct compounds. BPC-157 is a 15-amino-acid peptide derived from a gastric protein, with a mechanistic literature centered on VEGFR2-mediated angiogenesis. TB-500 is a 7-amino-acid acetylated fragment (residues 17–23) of the 43-amino-acid actin-sequestering protein thymosin beta-4, with a mechanistic literature centered on G-actin sequestration and the PINCH–ILK–Akt pathway.
Which has stronger published evidence — BPC-157 or TB-500?
The comparison depends on what is being asked. For published controlled animal-model work in tissue-repair injury models, the BPC-157 rodent literature is substantially larger and more methodologically consistent. For published human clinical trial data, the thymosin beta-4 family has a Phase 3 randomized controlled trial in neurotrophic keratopathy using full-length Tβ4 (RGN-259); BPC-157 has Phase I conference-proceedings safety data and an unpublished Phase II ulcerative colitis trial. The Phase 3 RGN-259 data are not directly applicable to the injected TB-500 heptapeptide fragment, which is the form sold under the TB-500 name.
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is the full-length 43-amino-acid actin-sequestering protein. TB-500 is a synthetic, N-acetylated heptapeptide corresponding to residues 17 through 23 of thymosin beta-4 — the actin-binding motif specifically. The N-terminal acetylation protects the heptapeptide from aminopeptidase degradation. The mechanistic and clinical research published on the thymosin beta-4 family has primarily used the full-length protein, not the heptapeptide; whether the heptapeptide fully recapitulates the parent protein’s pleiotropic activity in vivo is an unresolved question.
Is there published research on combining BPC-157 and TB-500?
There is no peer-reviewed published clinical or controlled preclinical study of a fixed-ratio BPC-157 + TB-500 combination product. Combination research consists of anecdotal practitioner reports and a limited number of unpublished animal observations. The pathway-level mechanistic rationale for combining the two — that BPC-157’s pro-angiogenic activity via VEGFR2–Akt–eNOS could complement thymosin beta-4’s cell-migration and survival activity via PINCH–ILK–Akt — has not been tested in published controlled studies.
Is either compound FDA-approved?
No. Neither BPC-157 nor TB-500 (nor full-length thymosin beta-4) is approved by the FDA, EMA, or any other regulatory authority for any indication. BPC-157 was advanced into Phase I and Phase II clinical trials by Pliva (PL 14736) for inflammatory bowel disease; full Phase II efficacy results were not published. Thymosin beta-4 was advanced into clinical development by RegeneRx (RGN-259 ophthalmic, RGN-352 injectable); a Phase 3 trial of topical RGN-259 in neurotrophic keratopathy reported positive results but the product has not received regulatory approval.
Is TB-500 prohibited in sport?
Yes. TB-500 (and thymosin beta-4 generally) is on the World Anti-Doping Agency prohibited list. Athletes subject to WADA jurisdiction should not use the compound in any context where they may be tested. This information is provided as a regulatory disclosure for researchers; the product is supplied for laboratory research only and not for human use.
References
-
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y · PubMed: 27847966
- Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000 · PubMed: 15565145
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004 · PubMed: 16099219
-
- Sosne G, Kleinman HK, et al. Phase 3 placebo-controlled clinical trial of 0.1% topical RGN-259 (Tβ4) in patients with neurotrophic keratopathy. Int J Mol Sci. 2022. (supportive citation flagged for PMID/DOI verification in review pass; details mirror TB-500 compound description)
-
- Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. doi:10.1002/jor.20096 · PubMed: 16583442
- Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012;1270:37-44. doi:10.1111/j.1749-6632.2012.06717.x · PubMed: 23050815
Citations 1–3 and 5–6 are verified-load-bearing references anchoring the structural argument of this comparison. Citation 4 is flagged for batch verification in the editorial QC pass.
For Research Use Only. The products described on this page are sold strictly for in vitro laboratory research and are not intended for human or animal consumption, diagnostic use, or therapeutic use. The published research summarized above is provided as scientific reference material. Nothing on this page constitutes medical advice, a therapeutic claim, or a recommendation for any use outside of a properly resourced and ethically reviewed research setting.